Design, Synthesis, and Evaluation of 99mTc-Labeled Proline Isonitrile Derivatives with Optimized Linker Lengths for Tumor SPECT Imaging
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5821-5832
DOI: 10.1021/acs.molpharmaceut.6c00846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 27.09.2026. Verfasst von Qing Ruan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Beam Technology of the Ministry of Education, College of Nuclear Science and Technology, Beijing Normal University, Beijing100875, …. Hauptthemen laut MEDLINE: Proline, Technetium, Tomography, Emission-Computed, Single-Photon, Radiopharmaceuticals. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Beijing Nova Program, Fundamental Research Funds for the Central Universities, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Amino acid metabolic imaging is among the important research directions in tumor molecular imaging. The highly active metabolism of proline in tumors, together with the abnormal expression of its key enzymes, makes it a promising target for tumor molecular imaging. To develop new proline transport-targeted tumor imaging agents, four l-proline isonitrile ligands (CN5Pro, CN6Pro, CN7Pro and CN8Pro) were synthesized and labeled with technetium-99m. All the complexes achieved >95% labeling yield with good stability. Biodistribution in S180 tumor-bearing mice revealed that [99mTc]Tc-CN7Pro exhibited the highest tumor uptake (1.05 ± 0.09% ID/g), a tumor/muscle ratio of 5.03, and predominant renal excretion. With respect to U87MG models, tumor uptake reached 2.47 ± 0.39% ID/g, confirming tumor imaging applicability. SPECT/CT imaging clearly revealed tumors, with uptake inhibited by excess l-proline. Cellular studies indicated uptake primarily via system A transporters, and the complex remained intact in vivo. Collectively, [99mTc]Tc-CN7Pro is convenient for labeling, achieves excellent targeting, and is very stable, making it a promising SPECT tumor imaging agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Beam Technology of the Ministry of Education, College of Nuclear Science and Technology, Beijing Normal University, Beijing100875, P. R. China.
- Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Norm…
ORCID-Profile: Qing Ruan, Peiwen Han, Yuhao Jiang, Junbo Zhang
Förderung
- Beijing Nova Program
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Ruan, Q., Yin, G., Feng, J., Ding, D., Han, P., Jiang, Y., & Zhang, J. (2026). Design, Synthesis, and Evaluation of 99mTc-Labeled Proline Isonitrile Derivatives with Optimized Linker Lengths for Tumor SPECT Imaging. Molecular Pharmaceutics, 23(11), 5821-5832. https://doi.org/10.1021/acs.molpharmaceut.6c00846
Vancouver
Ruan Q, Yin G, Feng J, Ding D, Han P, Jiang Y, et al. Design, Synthesis, and Evaluation of 99mTc-Labeled Proline Isonitrile Derivatives with Optimized Linker Lengths for Tumor SPECT Imaging. Molecular Pharmaceutics. 2026;23(11):5821-5832. doi:10.1021/acs.molpharmaceut.6c00846
BibTeX
@article{Ruan2026,
author = {Ruan, Qing and Yin, Guangxing and Feng, Junhong and Ding, Dajie and Han, Peiwen and Jiang, Yuhao and Zhang, Junbo},
title = {Design, Synthesis, and Evaluation of 99mTc-Labeled Proline Isonitrile Derivatives with Optimized Linker Lengths for Tumor SPECT Imaging},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5821--5832},
doi = {10.1021/acs.molpharmaceut.6c00846}
}
EUVIMED